IP Library Granted Patent US 10,117,963
Granted Patent B2
US 10,117,963 · App. 15/667,744 · Granted Nov 6, 2018

Medical adhesives for stopping heavy bleeding and sealing leakages

Inventors: Heike Heckroth (Odenthal, DE); Burkhard Köhler (Zierenberg, DE); Sebastian Dörr (Düsseldorf, DE)
Assignee: Adhesys Medical GmbH
A61L24/0094A61L24/046C08G18/089C08G18/10C08G18/4837C08L75/04C09J175/12A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,963
App. No.
15/667,744
Granted
Nov 6, 2018
Kind
B2
Abstract

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

Claims (25)

1. A method of staunching the loss of blood (haemostatic) or tissue fluids comprising:

a. providing a formulation comprising

A) an isocyanate-functional prepolymer obtained from

A1) an aliphatic isocyanate and

A2) a polyol component having a number-average molecular weight of greater than or equal to 400 g/mol and an average OH functionality of 2 to 6,

B) a curing component comprising

B1) an amino-functional aspartic ester of the general formula (I)

where

X is an organic radical obtained by removing the primary amino groups from 1,3-diaminopentane, 1,5-diaminopentane, or 1, 13-diamino-4,7,10-trioxatridecane,

R 1 and R 2 are ethyl and

n is 2

b. applying the formulation to a cell tissue; wherein the cell tissue comprises human or animal tissue; and

c. curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched,

wherein the formulation is applied in an in vivo application or an in vitro application.

2. The method according to claim 1 , wherein the curing component further comprises organic fillers which have a viscosity as measured to DIN 53019 at 23° C. in the range of from 10 to 6000 mPas.

3. The method according to claim 2 , wherein the formulation further comprises reaction products of the isocyanate-functional prepolymer with the organic fillers.

4. The method according to claim 1 , wherein the formulation further comprises reaction products of the isocyanate-functional prepolymer with the amino-functional aspartic ester.

5. The method according to claim 4 , wherein the formulation further comprises reaction products of the isocyanate-functional prepolymer with organic fillers.

6. The method according to claim 1 , wherein the curing component further comprises organic fillers which have a viscosity as measured to DIN 53019 at 23° C. in the range of from 10 to 6000 mPas and wherein the formulation further comprises reaction products of the isocyanate-functional prepolymer with the amino-functional aspartic ester and the organic fillers.

7. The method according to claim 1 , wherein the polyol component has a number-average molecular weight of 4000 to 8500 g/mol.

8. The method according to claim 1 , wherein the polyol component comprises a polyalkylene oxide polyether.

9. The method according to claim 8 , wherein the polyalkylene oxide polyether contain from 60% to 90% of ethylene oxide-based units, based on the total amount of alkylene oxide units.

10. The method according to claim 2 , wherein the organic fillers comprise polyether polyols.

11. The method according to claim 1 , wherein the formulation is cured for a period of time from 30 seconds to 10 minutes.

12. The method according to claim 1 , wherein the formulation is cured for a period of time from 30 seconds to 2 minutes.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: HECKROTH, HEIKE; KOEHLER, BURKHARD; DOERR, SEBASTIAN
To: ADHESYS MEDICAL GMBH
Reel/Frame 044596/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2017
From: HECKROTH, HEIKE; KOEHLER, BURKHARD; DOERR, SEBASTIAN
To: BAYER MATERIALSCIENCE AG
Reel/Frame 043283/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2017
From: BAYER MATERIALSCIENCE AG
To: MEDICAL ADHESIVE REVOLUTION GMBH
Reel/Frame 043283/0538 →
Priority Claims (1)
EP 08012901 · Jul 17, 2008 · regional
Continuity (2)
Continuation 13054673
Related Publication 20170326268A1 · Nov 16, 2017